Ranbaxy Claims ‘Buyer’s Remorse’ Behind U.S. ANDA Moves
This article was originally published in PharmAsia News
Suit argues the U.S. FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.
You may also be interested in...
FDA rescinds Ranbaxy’s esomeprazole and valganciclovir ANDA tentative approvals because of GMP compliance issues; firm loses its 180-day marketing exclusivity for valganciclovir but not for esomeprazole.
Although pharmaceutical company settlements in the millions of dollars now seem customary, a guilty plea to seven felonies could signal aggressive government pursuit of manufacturing and data integrity concerns.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.